{"protocolSection":{"identificationModule":{"nctId":"NCT01062698","orgStudyIdInfo":{"id":"2009-A00753-54"},"organization":{"fullName":"Central Hospital, Nancy, France","class":"OTHER"},"briefTitle":"Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke","officialTitle":"The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis","acronym":"THRACE"},"statusModule":{"statusVerifiedDate":"2017-07","overallStatus":"TERMINATED","whyStopped":"Efficacy","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-06"},"primaryCompletionDateStruct":{"date":"2015-12"},"completionDateStruct":{"date":"2016-03"},"studyFirstSubmitDate":"2010-02-03","studyFirstSubmitQcDate":"2010-02-03","studyFirstPostDateStruct":{"date":"2010-02-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-07-20","lastUpdatePostDateStruct":{"date":"2017-07-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Directeur de la Recherche et de l'Innovation","investigatorTitle":"Professor Serge BRACARD","investigatorAffiliation":"Central Hospital, Nancy, France"},"leadSponsor":{"name":"Central Hospital, Nancy, France","class":"OTHER"}},"descriptionModule":{"briefSummary":"THRACE is a controled, multicenter and randomized trial.\n\nThe primary objective of this study is to determine whether a combined approach intravenous thrombolysis (IV) + Mechanical thrombectomy is superior to the reference treatment with IV thrombolysis alone, in the 3 hours of onset of symptoms in patients with occlusion of proximal cerebral arteries and with a neurological impairment accident (National Institutes of Health Stroke Scale \\[NIHSS\\] â‰¥ 10).\n\nThe second objective is to determine the cost-effectiveness of this procedure compared to the standard (IV thrombolysis). The assumption is that the combined approach, by improving the clinical outcome and speed recovery, allows for lower overall costs to the IV thrombolysis in 3 months and less than or at worst neutral to 1 year."},"conditionsModule":{"conditions":["Cerebral Stroke","Cerebrovascular Accident"],"keywords":["mechanical Thrombectomy","CVA (Cerebrovascular Accident)","Cerebrovascular Accident, Acute"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["INVESTIGATOR"]}},"enrollmentInfo":{"count":412,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IV thrombolysis + thrombectomy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alteplase (rt-PA)/Actilyse","Procedure: Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)"]},{"label":"IV thrombolysis","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alteplase (rt-PA)/Actilyse"]}],"interventions":[{"type":"DRUG","name":"Alteplase (rt-PA)/Actilyse","description":"Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.","armGroupLabels":["IV thrombolysis","IV thrombolysis + thrombectomy"]},{"type":"PROCEDURE","name":"Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)","description":"Mechanic thrombectomy","armGroupLabels":["IV thrombolysis + thrombectomy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin Score (mRs )","timeFrame":"3 months after treatment"}],"secondaryOutcomes":[{"measure":"Quality of Life (Euroqol EQ-5D)","timeFrame":"3 months after treatment"},{"measure":"Barthel Score","timeFrame":"3 months after treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 10\\<=NIHSS Score=\\<25\n* Symptoms onset less than 4 hours\n* Occlusion of the intracranial carotid, the middle cerebral artery (M1) or the upper third of the basilar\n\nExclusion Criteria:\n\n* Contraindications for intravenous thrombolysis\n* Occlusion or stenosis of the pre-occlusive cervical internal carotid artery ipsilateral to the lesion\n* Any cause local prohibiting femoral catheterization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Serge Bracard, Pr","affiliation":"Central Hospital Nancy France (HNF)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Central Hospital Nancy (Central HNF)","city":"Nancy","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}}]},"referencesModule":{"references":[{"pmid":"35698971","type":"DERIVED","citation":"Janvier P, Kerleroux B, Turc G, Pasi M, Farhat W, Bricout N, Benzakoun J, Legrand L, Clarencon F, Bracard S, Oppenheim C, Boulouis G, Henon H, Naggara O, Ben Hassen W. TAGE Score for Symptomatic Intracranial Hemorrhage Prediction After Successful Endovascular Treatment in Acute Ischemic Stroke. Stroke. 2022 Sep;53(9):2809-2817. doi: 10.1161/STROKEAHA.121.038088. Epub 2022 Jun 14."},{"pmid":"34103393","type":"DERIVED","citation":"Riou-Comte N, Gory B, Soudant M, Zhu F, Xie Y, Humbertjean L, Mione G, Oppenheim C, Guillemin F, Bracard S, Richard S; THRACE investigators. Clinical imaging factors of excellent outcome after thrombolysis in large-vessel stroke: a THRACE subgroup analysis. Stroke Vasc Neurol. 2021 Dec;6(4):631-639. doi: 10.1136/svn-2020-000852. Epub 2021 Jun 8."},{"pmid":"33184069","type":"DERIVED","citation":"Derraz I, Pou M, Labreuche J, Legrand L, Soize S, Tisserand M, Rosso C, Piotin M, Boulouis G, Oppenheim C, Naggara O, Bracard S, Clarencon F, Lapergue B, Bourcier R; ASTER and the THRACE Trials Investigators. Clot Burden Score and Collateral Status and Their Impact on Functional Outcome in Acute Ischemic Stroke. AJNR Am J Neuroradiol. 2021 Jan;42(1):42-48. doi: 10.3174/ajnr.A6865. Epub 2020 Nov 12."},{"pmid":"31519778","type":"DERIVED","citation":"Boulouis G, Bricout N, Benhassen W, Ferrigno M, Turc G, Bretzner M, Benzakoun J, Seners P, Personnic T, Legrand L, Trystram D, Rodriguez-Regent C, Charidimou A, Rost NS, Bracard S, Cordonnier C, Oppenheim C, Naggara O, Henon H. White matter hyperintensity burden in patients with ischemic stroke treated with thrombectomy. Neurology. 2019 Oct 15;93(16):e1498-e1506. doi: 10.1212/WNL.0000000000008317. Epub 2019 Sep 13."},{"pmid":"30744542","type":"DERIVED","citation":"Provost C, Soudant M, Legrand L, Ben Hassen W, Xie Y, Soize S, Bourcier R, Benzakoun J, Edjlali M, Boulouis G, Raoult H, Guillemin F, Naggara O, Bracard S, Oppenheim C. Magnetic Resonance Imaging or Computed Tomography Before Treatment in Acute Ischemic Stroke. Stroke. 2019 Mar;50(3):659-664. doi: 10.1161/STROKEAHA.118.023882."},{"pmid":"28916667","type":"DERIVED","citation":"Achit H, Soudant M, Hosseini K, Bannay A, Epstein J, Bracard S, Guillemin F; THRACE Investigators. Cost-Effectiveness of Thrombectomy in Patients With Acute Ischemic Stroke: The THRACE Randomized Controlled Trial. Stroke. 2017 Oct;48(10):2843-2847. doi: 10.1161/STROKEAHA.117.017856. Epub 2017 Sep 15."},{"pmid":"27567239","type":"DERIVED","citation":"Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, Guillemin F; THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016 Oct;15(11):1138-47. doi: 10.1016/S1474-4422(16)30177-6. Epub 2016 Aug 23. Erratum In: Lancet Neurol. 2016 Nov;15(12):1203."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Airflow","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}